Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amarnath Sharma

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Antimicrobial Agents and Chemotherapy|November 1, 2006
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapyPing Liu, Grover Foster, Robert Labadie, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2018
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitisChuanpu Hu, Omoniyi J Adedokun, Liping Zhang, et al.
Journal of Clinical Pharmacology|November 21, 2007
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjectsPing Liu, Grover Foster, Robert R LaBadie, et al.
The Nigerian Postgraduate Medical Journal|January 2, 2026
Sex-specific Anthropometric Variations and the Influence of Central Obesity on Thyroid Hormone Regulation: A Cross-sectional StudyLaimayum Amarnath Sharma, Jeneth Karmakar, Khuraijam Ranendra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapyDonghua Yin, Franzanne Vreeland, Larry J Schaaf, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2005
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma modelsQingyu Zhou, Malini Olivo, Karen Yee Kar Lye, et al.
Clinical Drug Investigation|October 21, 2020
Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus ErythematosusZhenling Yao, Laura Loggia, Damien Fink, et al.
Oncology Reports|April 10, 2003
The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agentsBalram Chowbay, Amarnath Sharma, Qing-Yu Zhou, et al.
Journal of Clinical Pharmacology|June 15, 2018
Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid ArthritisYan Xu, Chuanpu Hu, Yanli Zhuang, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2006
Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimenPing Liu, Hameed Allaudeen, Richa Chandra, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Antimicrobial Agents and Chemotherapy|November 1, 2006
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapyPing Liu, Grover Foster, Robert Labadie, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2018
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitisChuanpu Hu, Omoniyi J Adedokun, Liping Zhang, et al.
Journal of Clinical Pharmacology|November 21, 2007
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjectsPing Liu, Grover Foster, Robert R LaBadie, et al.
The Nigerian Postgraduate Medical Journal|January 2, 2026
Sex-specific Anthropometric Variations and the Influence of Central Obesity on Thyroid Hormone Regulation: A Cross-sectional StudyLaimayum Amarnath Sharma, Jeneth Karmakar, Khuraijam Ranendra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapyDonghua Yin, Franzanne Vreeland, Larry J Schaaf, et al.
Cancer Chemotherapy and Pharmacology|July 8, 2005
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma modelsQingyu Zhou, Malini Olivo, Karen Yee Kar Lye, et al.
Clinical Drug Investigation|October 21, 2020
Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus ErythematosusZhenling Yao, Laura Loggia, Damien Fink, et al.
Oncology Reports|April 10, 2003
The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agentsBalram Chowbay, Amarnath Sharma, Qing-Yu Zhou, et al.
Journal of Clinical Pharmacology|June 15, 2018
Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid ArthritisYan Xu, Chuanpu Hu, Yanli Zhuang, et al.
Antimicrobial Agents and Chemotherapy|October 25, 2006
Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimenPing Liu, Hameed Allaudeen, Richa Chandra, et al.
Pageof 5